No-Wash Immunoassay for IFN-β

Catalog Number:


Overview
Protocols
Specifications
Resources
Related Products

Quantify IFN-β Release Without Tedious Wash Steps

IFN-β is an essential mediator of the innate immune response. It has potent antiviral properties, regulates the activity of various immune cells, and exhibits anti-inflammatory effects. IFN-β is used as a therapeutic agent to mitigate inflammation in diseases such as multiple sclerosis.

The Lumit® IFN-β Immunoassay quantitatively measures released IFN-β in cell culture samples using a simple, no-wash protocol. Just add labeled antibodies to the sample, add detection reagent and read luminescent signal using a standard plate-reading luminometer. The entire protocol is completed in less than 70 minutes! The assay can be used directly on cells in culture or culture medium transferred to a separate assay plate.

How the Lumit® IFN-β Immunoassay Works

Primary antibodies to IFN-β were selected for their specific and sensitive detection and labeled with the LgBiT and SmBiT subunits of NanoBiT® Luciferase. In the presence of IFN-β, the subunits are brought together to form an active luciferase enzyme. Addition of optimized substrate generates a bright luminescent signal proportional to IFN-β levels.

Schematic of Lumit™ IL-8 Immunoassay concept showing LgBiT and SmBiT binding protein binding to IL-8 and forming NanoBiT® Luciferase.

Simple One-Plate Protocol Requires No Wash Steps

Lumit™ IL-8 (Human) Immunoassay workflow.

Broad Linear Range of Lumit® IFN-β Detection

The pico- to nanomolar linear detection range of the Lumit® IFN-β Immunoassay covers expected concentrations for most cell models.

Graph showing standard curve for Lumit™ IFN-β (Human) Immunoassay.

Specification

Lumit® IFN-β (Human) Immunoassay

Dynamic Range

18.2–25,000pg/ml

Limit of Detection (LOD)

5.3pg/ml (3 SD above background)

Minimal Detectable Dose (MDD)

3.6pg/ml (2 SD above background)

Assay Time

70 minutes

Sample Type

Cell culture supernatants

SD=Standard Deviation

 

Need to measure a different target?

View our growing portfolio of
Lumit® Immunoassays.

For a biotech that understands time is of significant value, the Lumit® Immunoassays are an essential way for us to gather reliable data fast so that we can reach conclusions and make decisions sooner.

Jonathan Chow, Principal Scientist, Corner Therapeutics

Patents and Disclaimers

U.S. Pat. No. 8,809,529, European Pat. No. 2635582, Japanese Pat. No. 5889910 and other patents and patents pending.

U.S. Pat. Nos. 9,797,889, 9,797,890, 10,107,800 and 10,648,971 and other patents and patents pending.

Optimizing the Lumit® IL-6 Immunoassay for High-Throughput Drug Screening

In this webinar, we share key considerations for scaling Lumit® Immunoassays from a single 96-well plate to many 364-well plates and offer tips for optimizing Lumit® Immunoassays for HTS applications. You will also hear Galapagos scientist Dr. Nick Verstraeten share how his team used the Lumit® IL-6 Immunoassay in a screening campaign for antiviral drugs.

View On-Demand Webinar

Protocols

No protocols available

Specifications

Catalog Number: